P urines exert potent and diverse effects on the cardiovascular system; the physiological significance of these actions is receiving increasing attention. Much progress has been made since the initial observations of Drury and Szent-Gyorgyil of the effects of adenosine and AMP on the mammalian heart and circulation; they showed that intravenous injection of these purines into whole animals induced a decrease in heart rate and arterial blood pressure, dilation of coronary blood vessels, and inhibition of intestinal movements. Subsequently, observations of the potent vasodilator actions of extracellular ATP led to the rapid expansion of the field of cardiovascular pharmacology of purines.2,3 Two of the first studies to suggest physiological roles for adenosine and ATP in local regulation of blood flow resulted in 1) the observation that stimulation of the rabbit great auricular nerve caused antidromic dilatation of the ear vessels and concomitant release of ATP, suggesting a role for ATP in this neurally mediated response,4 and later, 2) the detection of breakdown products of adenosine in the cardiac perfusate after a period of hypoxia, which formed the basis for the hypothesis that adenosine is a physiological regulator of coronary blood flow. Subdivision of P2-purinoceptors has also recently been suggested (see "Subclassification of P2-Purinoceptors").
urines exert potent and diverse effects on the cardiovascular system; the physiological significance of these actions is receiving increasing attention. Much progress has been made since the initial observations of Drury and Szent-Gyorgyil of the effects of adenosine and AMP on the mammalian heart and circulation; they showed that intravenous injection of these purines into whole animals induced a decrease in heart rate and arterial blood pressure, dilation of coronary blood vessels, and inhibition of intestinal movements. Subsequently, observations of the potent vasodilator actions of extracellular ATP led to the rapid expansion of the field of cardiovascular pharmacology of purines.2,3 Two of the first studies to suggest physiological roles for adenosine and ATP in local regulation of blood flow resulted in 1) the observation that stimulation of the rabbit great auricular nerve caused antidromic dilatation of the ear vessels and concomitant release of ATP, suggesting a role for ATP in this neurally mediated response,4 and later, 2) the detection of breakdown products of adenosine in the cardiac perfusate after a period of hypoxia, which formed the basis for the hypothesis that adenosine is a physiological regulator of coronary blood flow.5 It is now clear that these early studies predicted examples of only two of the many different roles played by adenosine and ATP in the physiological regulation of the cardiovascular system.
The heterogeneity of the purine receptor population was first formally recognized in 1978, when Burnstock named two classes, P, and P2, and proposed criteria for their identification. 6 An agonist potency order of adenosine > AMP > ADP > ATP; selective antagonism by methylxanthines; and receptor-activated changes in intracellular cyclic AMP (cAMP) levels identified the P1-purinoceptor. At the P2-purinoceptor, the agonist potency order was proposed to be ATP > ADP > AMP > adenosine; there was no antagonism by methylxanthines and no change in intracellular cAMP levels after receptor occupancy. However, in some cases, there was stimulation of prostaglandin biosynthesis. P,-Purinoceptors have been further subdivided into A, and A2 (Reference 7) or Ri and Ra (Reference 8) (according to alternative systems of nomenclature), which inhibit (A,/Rj) or activate (A2/Ra) adenylate cyclase.
Subdivision of P2-purinoceptors has also recently been suggested (see "Subclassification of P2-Purinoceptors").
The direct effects of purine nucleotides can be manifested as vasoconstrictor or vasodilator responses, which have been described in a large number of vessels and vascular beds (see "Actions of P2 Agonists in Animals and in Humans" and References 9 and 10). Evidence has been presented for a number of different local sources of purine nucleotides: ATP has been shown to be released as a cotransmitter with noradrenaline from perivascular sympathetic nerves and as a transmitter from purinergic and sensory nerves," and ATP and ADP are components of blood-borne elements, such as platelets and erythrocytes, and can also be released from endothelial and smooth muscle cells. '2 The relation between the release of purines from these sources and stimuli such as ischemia, hypoxia, and sheer stress is the subject of much investigation. Several factors are important in determining the direction of the vascular response elicited by purine nucleotides, including the nature of the purinoceptor subtype involved and its location in relation to the structural components of the vascular wall, although there is usually a close correlation between the two. Activation of specific P2-purinoceptors located on the smooth muscle can produce direct vasoconstrictor or vasodilator effects; activation of purinoceptors located on endothelial cells usually produces relaxation via production of endothelium-derived relaxing factor (EDRF),13 although endothelium-mediated contractions can also occur.14 In light of evidence for the crucial role played by the vascular endothelium in the relaxant responses elicited by many agents, including ATP and ADP,15 there is particular interest in mechanisms that perturb endothelial function or integrity because these have the potential to abolish a response in one direction (endothelially mediated vasodilatation) to allow an opposite effect (vasoconstriction at the underlying smooth muscle) to take place.
Prejunctional and postjunctional neuromodulatory effects of purines have been described. Prejunctional 2 Circulation Vol 84, No 1 July 1991 inhibition of noradrenaline release from sympathetic nerves by ATP and adenosine has been demonstrated in many blood vessels.16'7 Most often, the prejunctional inhibitory effects of ATP are mediated through the P,-purinoceptor after its ectoenzymatic breakdown to adenosine because the prejunctional inhibition is blocked by methylxanthines but not mimicked by the stable analogue of ATP, a,,3-methylene ATP. In some tissues, including the rat caudal artery and rat vas deferens, a prejunctional P3-receptor has been proposed that mediates the suppression of noradrenaline release.18'9 It has been suggested that this purinoceptor recognizes the structure of both nucleosides and nucleotides because it is antagonized by 8-phenyltheophylline and other P, antagonists, yet it is activated by 83 In the rat mesenteric arterial bed preparation, perivascular sympathetic nerve stimulation produces a contractile response that is entirely67 or almost entirely66 blocked by prazosin. However, in myograph-mounted small mesenteric arteries (150- 250-gm diameter) from the same species, both the EJPs and a significant proportion of the contractile response are blocked by a,,8-methylene ATP.63, 68 This apparent anomaly raises some important points about sympathetic cotransmission. First, this may be a consequence of different proportions of ATP used as a cotransmitter in mesenteric resistance vessels compared with larger mesenteric arteries (which contribute to the vascular resistance of the whole bed preparation). Second, this difference may be related to the different parameters of stimulation that are used to elicit contraction in the two preparations. In the rabbit ear artery, it has been shown that the purinergic component is optimal with short bursts of low frequency stimulation, whereas longer durations of higher frequency favor adrenergic transmission.69 The parameters of stimulation required to elicit contraction of the mesenteric arterial bed are of relatively high frequency and long duration, whereas the small isolated vessels will respond to stimulation at lower frequencies and of shorter duration. This point is supported by the observation that in small mesenteric arteries of the rat, 80% of the contraction to a single stimulation at high frequency is resistant to a-adrenoceptor blockade by prazosin, whereas with increasing duration of stimulation, noradrenaline becomes the dominant transmitter.68
Several possibilities for the functional significance of cotransmission have been discussed by Burnstock and Kennedy.9 First, different proportions of cotransmitters can be released according to the number, frequency, and pattern of impulses (i.e., the relative rates of release of cotransmitters may depend on the functional activity of the nerve terminal). The results of the experiments with the rabbit ear artery and isolated rat mesenteric vessels discussed above are consistent with this idea. Second, there may be differences in the time course of release and in events occurring after discharge of transmitter from the nerve terminal (i.e., in diffusion, postjunctional action, or inactivation of cotransmitters). The relatively short duration for which transmitters are in transit in the extraterminal space makes it difficult to discriminate among these events; however, there are many examples of the delayed action of a peptide acting as a cotransmitter with a classic transmitter.70 Third, corelease of two transmitters may be linked to a postjunctional synergistic interaction between two substances because of events occurring at or beyond the cell membrane. A synergistic interaction between ATP and noradrenaline has been described in the rat femoral artery,71 guinea pig and rat portal veins,72 and rat mesenteric arterial bed. 73 Adrenergic and purinergic components of sympathetic transmission may be differentially affected by physiological and pathophysiological conditions. It has been suggested that the relative importance of cotransmitters may vary with age. 74 In the rat tail artery, younger rats apparently produce entirely ATP-mediated contractions,75 whereas mesenteric vessels from older rats do not always produce a purinergic response,68 which is consistent with the notion of a higher ATP-to-noradrenaline ratio in sympathetic nerves of younger animals. In spontaneously hypertensive rats, it has been suggested that the ATP component in sympathetic nerves of rat tail arteries is more prominent.61
The radioligand 3H-a,4-methylene ATP, which has been used to preferentially localize P2x-purinoceptors in vascular and nonvascular tissues,76 may prove valuable in quantifying changes in this receptor population with age and in disease.
P2x-Purinoceptors and Nonsympathetic Transmission
Nonsympathetic purinergic excitatory transmission has recently been described in rat intrapulmonary arteries. 77 The P2Y-purinoceptor is also linked to the production of prostacyclin (PGI2), which may contribute to vasodilatation in some vessels. Endothelial cells are prolific producers of prostaglandins, and both ATP and ADP stimulate the release of prostaglandin from vascular beds108"109 and PGL from endothelial cells in culture.1"0"'11 2-Methylthio ATP mimics this response, whereas a,3-methylene ATP is inactive, confirming the involvement of the P2Y-purinoceptor. The mobilization of intracellular Ca'+ as a consequence of generation of inositol 1,4,5-triphosphate from the hydrolysis of membrane-bound phosphatidyl inositol 4,5-biphosphate is important in the mechanism of production of PGI2, whereas extracellular Ca2' appears to be more important in the generation of nitric oxide.12 Although PGI2 is a potent relaxing agent in some systems, it is more likely to be involved in homeostatic mechanisms, whereas EDRF is relatively more important in causing vascular relaxation.
Actions of P2 Agonists in Animals and in Humans Isolated Vessels
The response of a vessel to exogenous ATP and its analogues will be a balance between opposing effects mediated by P2X-and P2Y-purinoceptors. A contribution of P1-purinoceptors, largely following ectoenzymatic breakdown of ATP to adenosine, also has to be considered. Manipulations of the tone of isolated vessels can be used in pharmacological studies to favor either of these two P2-purinoceptor subtypes (Figure 3) . Hence, at low tone, the vascular response to ATP is generally a contraction exerted via P2X-purinoceptors on the smooth muscle, whereas when the tone is raised, relaxant effects via P2Y-purinoceptors on endothelial cells are favored. This is useful in the identification and characterization of receptor subtypes, although closer approximations of "real" The potent cardiodilatory effects of ATP have also been long known. In 1934, Gillespie2 showed that injection of ATP into the isolated rabbit heart caused an increase in coronary blood flow. The rat coronary vascular bed responds to ATP by producing both vasoconstriction and vasodilatation, manifest as a biphasic response, which is mediated through activation of P2X-and P2Y-purinoceptors, respectively.132 A study by Paddle and Burnstock133 showed that ATP is released during hypoxic stimulation of the heart and provided early, although indirect, evidence for a role for ATP as a physiological modulator (along with adenosine) of coronary flow. In a more recent study, Hopwood et al102 showed that hydroquinone, an antagonist of EDRF-mediated effects, blocked both the dilatation to 2-methylthio ATP at the P2Y-purinoceptor and the hypoxic relaxation, implicating both ATP and EDRF in the cardiac dilatation to hypoxia. The source of this ATP is not entirely clear. ATP has been shown to be released into the perfusate of the working rat heart in response to hypoxia134 and from hypoxic cardiomyocytes'35 in concentrations high enough to account for the dilator response. However, purinergic nerves136 and endothelial cells98'137 represent alternative sources of releasable ATP. Isolated cardiac endothelial cells in culture have recently been shown to contain and release large amounts of adenine nucleotides,138 which is consistent with the hypothesis that endothelial cells represent a physiological source of the ATP that is released during hypoxia. 139 ATP and ADP cause vasodilatation of the hindlimb of the cat.140 ATP and ADP were shown to be more potent than adenosine in this preparation, and the order of vasodilator potency of 2-methylthio ATP > ADP > ATP > f3,y-methylene ATP, a,43-methylene ATP is consistent with an action at P2y-purinoceptors.34
In the rat hindlimb, a biphasic response to ATP is produced, with vasoconstriction being preceded by transient vasodilatation, although 5 -hydroxytryptamine is likely to be the mediator of the pressor response.14' In the perfused rabbit hindlimb in vivo, the vasodilatation resulting from ATP was severely reduced (by 88%) by gossypol, a potent and irreversible inhibitor of EDRF; in some cases, vasoconstrictor responses were then observed.'42"143 It is possible that ATP contributes to the local regulation of blood flow in skeletal muscle during exercise because it has been shown to be released from active frog skeletal muscle in vitro122 and is present in the venous effluent of contracting human forearm muscles.144
The potent effects of purine nucleotides on cerebral blood flow (they can cause either vasodilatation or vasoconstriction) has led to the hypothesis that they are involved in cerebral vasospasm and migraine.145-47 It has also been suggested that they may be released from the brain, possibly from endothelial cells, as part of a protective mechanism of vasodilatation in response to hypoxia.147
In the isolated, perfused rabbit liver at low tone, ATP, 2-methylthio ATP, and a,f3-methylene ATP produce vasoconstriction, with agonist potency order indicating an effect at P2X-purinoceptors. In the raised-tone preparation, ATP and 2-methylthio ATP but not a,,3-methylene ATP elicit vasodilatation consistent with an action at P2Y-purinoceptors; furthermore, vasodilator responses were not affected by the P,-antagonist 8-phenyltheophylline, confirming that relaxation to ATP did not occur at Pi-purinoceptors after breakdown to adenosine. 148 The attenuation of relaxations to ATP but not those to adenosine by the nitric oxide to L-arginine antagonist LNOARG methyl ester implicates nitric oxide produced by endothelial cells as a mediator of the vasodilator response to ATP.105 Vasoconstrictor responses to ATP and ADP have also been described in the isolated, perfused rat liver preparation.149 The functional significance of these receptors in the hepatic vasculature may be related to the participation of P2-purinoceptor mechanisms in the compensatory dilatation of the hepatic arterial vasculature in response to reductions in portal blood flow, the "buffer response,"150 which has until recently15' been largely attributed to P,-purinoceptor mechanisms.
P2-Purinoceptor subtypes have been characterized in the isolated rat mesenteric arterial bed100 ( Figure  3 ). ATP and its analogues produced vasoconstriction of the preparation at low tone with a potency order of a,,3-methylene ATP > 2-methylthio ATP > ATP, which is characteristic of an action at P2x-purinoceptors. Vasodilatation of the raised-tone preparation was elicited by 2-methylthio ATP > ATP, whereas a,,8-methylene ATP was without effect, which is characteristic of effects mediated at P2y-purinoceptors. Removal of the endothelium did not reduce P2X-mediated contraction but abolished P2Y-mediated relaxation, indicating that these receptors are present on the smooth muscle and on endothelial cells, respectively, where they are likely to contribute to local regulation of mesenteric blood flow.
Whole Animals When ATP is infused or injected into animals and humans, it produces a profound decrease in blood pressure, which is often associated with bradycardia. Early studies include those of Gillespie,2 who showed that ATP injected into the jugular vein of the cat caused a decrease in systemic blood pressure. Wayne et al152 showed that ATP injected into the jugular vein of the guinea pig had marked effects on the heart, causing a depression of normal function with sinus slowing and the appearance of heart block as well as a decrease in blood pressure. Similarly, Emmelin and Feldberg153 found that bradycardia and a decrease in systemic blood pressure accompanied intravenous or intra-arterial injection of ATP in cats, rabbits, and dogs. 153 The suggestion of an involvement of the vagal reflex in the electrophysiological actions of ATP but not of adenosine was later confirmed in the canine heart where it was shown that the negative chronotropic and dromotropic actions on the sinoatrial and atrioventricular nodes, respectively, were attenuated by either atropine or vagotomy plus autonomic blockade with proprano1ol.154'55 Forrester et no difference between the effectiveness of ATP and that of adenosine. These observed differences may be the result of different routes of administration (carotid artery versus femoral vein) and modes of administration (dose versus continuous infusion) used by the different investigators.
In these studies, it appears that a large part of the effects of ATP are mediated after its breakdown to adenosine. Sollevi et al157 showed that inferior vena cava infusion of adenosine and ATP in dogs produced equal decreases in systemic vascular resistance and demonstrated that ATP was largely degraded in the lung before it reached the vascular arterial bed. More recently, it has been suggested that the depressor effects on systemic arterial pressure of ATP injected intra-arterially in the anesthetized rat are effected at P,-purinoceptors after breakdown to adenosine, although the potent vasoconstrictor actions of a,,3-methylene ATP imply a direct action at P2-purinoceptors.158 It is not yet clear what the implications are from the recent discovery that in vivo administration of AMP, ADP, or ATP, but not adenosine, results in an expansion of red blood cell ATP pools and blood plasma ATP levels,159 although it has been suggested to explain the differences in cardiovascular effects of ATP administration compared with adenosine administration in humans.
Because of its potent vasodilator properties in most vascular beds, ATP has been investigated with respect to pharmacologically induced hypotension, which is frequently used during surgery to optimize operating conditions and decrease chances of hemorrhage. For example, ATP infusion has recently been used by Aso et al160 to control blood pressure in the treatment of pheochromocytoma cases. 160 The advantages of ATP-induced hypotension are the absence of tachyphylaxis, the stability of blood pressure with well-preserved hemodynamics, fast onset, and rapid reversibility with no rebound hypotension; however, many authors agree that metabolic acidosis and cardiac arrhythmias impose constraints on its clinical use.161'162 Furthermore, the negative inotropic and chronotropic effects that are responsible for the lack of a tachycardiac response during hypotension can, with excessively large doses of adenyl compounds, be responsible for complete atrioventricular block and asystole. 152, 163 ATP has been used successfully, given intravenously or intra-arterially, to treat various pathological conditions of the coronary and peripheral circulations. There are several examples in which ATP has been used in the treatment of cardiovascular disease, including arthritis (see Reference 164) . Recently, intravenous infusion of ATP in humans was investigated with regard to its therapeutic use in patients with chronic obstructive pulmonary disease'65; ATP produced a significant pulmonary vasodilatation and at the low infusion rates used was well tolerated, short acting, and selective, although there was an undesirable rebound vasoconstriction on cessation of infusion and a worsened hypoxemia. The potent depressant effects of ATP on the sinoatrial and ventricular nodes of the human heart have resulted in the recommendation of ATP for the treatment of various types of tachycardia.'63,166,J67 Summary Characterization of P2-purinoceptor subtypes has facilitated understanding of the many diverse effects produced by purine nucleotides (see Figure 4) 
